Evidence map›Paper›PMID 32959230›Full record

ArticleInternational journal of clinical oncology2021

UroVysion

Hidehiro Iwata, Naoto Sassa, Masashi Kato, Yota Murase, Shuko Seko, Hideji Kawanishi, Ryohei Hattori, Momokazu Gotoh, Toyonori Tsuzuki

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Hidehiro IwataDepartment of Surgical Pathology, Aichi Medical University Hospital, 1-1 Yazakokarimata, Nagakute, 480-1195, Japan.
Naoto SassaDepartment of Urology, Aichi Medical University Hospital, 1-1 Yazakokarimata, Nagakute, 480-1195, Japan.
Masashi KatoDepartment of Urology, Nagoya University Graduate School of Medicine, Tsuruma-Cho, Showa-Ku, Nagoya, 466-0065, Japan.
Yota MuraseDepartment of Surgical Pathology, Aichi Medical University Hospital, 1-1 Yazakokarimata, Nagakute, 480-1195, Japan.
Shuko SekoDepartment of Pathology, Japanese Red Cross Nagoya Daini Hospital, 2-9 Myoken-Cho, Showa-Ku, Nagoya, 466-8650, Japan.
Hideji KawanishiDepartment of Urology, Aichi Medical University Hospital, 1-1 Yazakokarimata, Nagakute, 480-1195, Japan.
Ryohei HattoriDepartment of Urology, Japanese Red Cross Nagoya Daiichi Hospital, 3-35 Douge-Cho, Nakamura-Ku, Nagoya, 453-8511, Japan.
Momokazu GotohDepartment of Urology, Nagoya University Graduate School of Medicine, Tsuruma-Cho, Showa-Ku, Nagoya, 466-0065, Japan.
Toyonori TsuzukiDepartment of Surgical Pathology, Aichi Medical University Hospital, 1-1 Yazakokarimata, Nagakute, 480-1195, Japan. tsuzuki@aichi-med-u.ac.jp.ORCID http://orcid.org/0000-0002-4855-4366
Aichi Medical University Hospital · JPNagoya University · JPJapanese Red Cross Nagoya Daiichi Hospital · JPJapanese Red Cross Nagoya Daini Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIntravesical recurrence (IVR) after radical nephroureterectomy (RNU) for urothelial carcinoma of the upper urinary tract (UCUUT) is common. One of the mechanisms driving this is the implantation of cancer cells from the UCUUT at the RNUs. Therefore, their detection after RNU can assist in predicting IVR. This study aimed to examine the utility of UroVysion

methodsWe prospectively enrolled 65 patients who received RNU for high-grade UCUUT between October 2013 and April 2017.

resultsOf the 65 patients, 54 (83.1%) who had both bladder urine samples available immediately after RNU (0 postoperative days: POD) and 5 days after RNU (5POD) were selected. We performed UroVysion

conclusionMultiple urine tests using UroVysion

Indexed as

Carcinoma, Transitional CellUrinary Bladder NeoplasmsUrinary TractHumansNeoplasm Recurrence, LocalNephrectomyNephroureterectomyProspective StudiesRetrospective StudiesIntravesicular recurrenceNephroureterectomyUrine cytologyUrothelial carcinoma of the upper urinary tractUroVysion

Identifiers

PMID32959230
OpenAlexW3087717688

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.